Skip to main content
Figure 4 | BMC Family Practice

Figure 4

From: Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies

Figure 4

Relative risks for the most frequent adverse events for pregabalin 300 mg/day versus placebo by age group. The left panel shows the percentage of patients in each age group that reported a particular adverse event by treatment group. The right panel shows the relative risk of given adverse events in each age group for pregabalin versus placebo. CI: confidence interval; WG: weight gain; Somn: somnolence; Inf: infection; PE: peripheral edema; DM: dry mouth; DZ: dizziness; Asth: asthenia.

Back to article page

BMC Primary Care

ISSN: 2731-4553

Contact us